ECSP21080966A - Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2 - Google Patents

Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2

Info

Publication number
ECSP21080966A
ECSP21080966A ECSENADI202180966A ECDI202180966A ECSP21080966A EC SP21080966 A ECSP21080966 A EC SP21080966A EC SENADI202180966 A ECSENADI202180966 A EC SENADI202180966A EC DI202180966 A ECDI202180966 A EC DI202180966A EC SP21080966 A ECSP21080966 A EC SP21080966A
Authority
EC
Ecuador
Prior art keywords
mrgx2
thiadiazine
benzo
inhibitors
amino
Prior art date
Application number
ECSENADI202180966A
Other languages
English (en)
Inventor
Tony Gibson
Angie Vassar
Mitsunori Kono
Steve Swann
Feng Zhou
Allison Chambers
Masaki Seto
Zenyu Shiokawa
Jason Pickens
Simone Bigi
Original Assignee
Solent Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solent Therapeutics Llc filed Critical Solent Therapeutics Llc
Publication of ECSP21080966A publication Critical patent/ECSP21080966A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
    • C07D285/32—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de la Fórmula 1, tautómeros de los mismos, y sales farmacéuticamente aceptables de los compuestos o tautómeros, en donde L, R1, R2, R3, R4 y R5 son definidos en la especificación. Esta descripción también se refiere a materiales y métodos para preparar compuestos de la Fórmula 1, a las composiciones farmacéuticas que las contienen, y a su uso para tratar enfermedades, trastornos o afecciones asociadas con MRGX2.
ECSENADI202180966A 2019-04-29 2021-11-15 Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2 ECSP21080966A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962840344P 2019-04-29 2019-04-29

Publications (1)

Publication Number Publication Date
ECSP21080966A true ECSP21080966A (es) 2022-01-31

Family

ID=70779887

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202180966A ECSP21080966A (es) 2019-04-29 2021-11-15 Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2

Country Status (22)

Country Link
US (2) US12247015B2 (es)
EP (1) EP3962901A1 (es)
JP (1) JP7574215B2 (es)
KR (2) KR102922478B1 (es)
CN (2) CN114072393B (es)
AR (1) AR119728A1 (es)
AU (1) AU2020266529B2 (es)
BR (1) BR112021021508A2 (es)
CL (1) CL2021002805A1 (es)
CO (1) CO2021014155A2 (es)
CR (1) CR20210544A (es)
DO (1) DOP2021000223A (es)
EC (1) ECSP21080966A (es)
IL (1) IL287521B2 (es)
JO (1) JOP20210275A1 (es)
MA (1) MA55804A (es)
MX (1) MX2021013135A (es)
PE (1) PE20220425A1 (es)
PH (1) PH12021552760A1 (es)
SG (1) SG11202111717XA (es)
TW (1) TWI846868B (es)
WO (1) WO2020223255A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12247015B2 (en) 2019-04-29 2025-03-11 Solent Therapeutics, Llc 3-amino-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2
AR122450A1 (es) * 2020-05-08 2022-09-14 Lilly Co Eli Compuestos de (trifluorometil)pirimidin-2-amina
WO2022152853A1 (en) * 2021-01-15 2022-07-21 Glaxosmithkline Intellectual Property Development Limited Antagonists of mrgx2
WO2022152852A1 (en) * 2021-01-15 2022-07-21 Glaxosmithkline Intellectual Property Development Limited Antagonists of mrgx2
WO2024183806A1 (en) * 2023-03-08 2024-09-12 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
CN121712780A (zh) * 2023-08-17 2026-03-20 赛诺菲 噻吩并噻二嗪、其制备及其治疗应用
US20250084063A1 (en) 2023-08-18 2025-03-13 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
TW202517273A (zh) * 2023-10-06 2025-05-01 美商伊賽恩特製藥公司 Ｍｒｇｐｒｘ２調節劑及相關治療方法
WO2025140531A1 (zh) * 2023-12-29 2025-07-03 深圳阿尔法分子科技有限责任公司 喹诺酮类化合物及其用途
WO2025160430A1 (en) 2024-01-25 2025-07-31 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
WO2025222040A1 (en) 2024-04-19 2025-10-23 Escient Pharmaceuticals, Inc. Mrgprx2 modulators for use in treating mrgprx2 dependent conditions in subjects with low ige
WO2026009854A1 (ja) * 2024-07-01 2026-01-08 日本たばこ産業株式会社 ピリダジノン化合物及びその医薬用途
WO2026033047A1 (en) * 2024-08-08 2026-02-12 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine derivatives as mrgx2 antagonists

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2757999A1 (de) * 1977-12-24 1979-06-28 Bayer Ag Substituierte aminoalkylenamino- 1.2.4-benzothiadiazine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
EP0105732A3 (en) 1982-10-01 1985-09-04 Beecham Group Plc Histamine h2 receptor antagonists of the benzisothiazole amino and benzthiadiazine amino series
EP0386931A1 (en) 1989-03-04 1990-09-12 Konica Corporation A novel cyan coupler
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US6242443B1 (en) 1996-06-21 2001-06-05 Novo Nordisk Ais 1,2,4-benzothiadiazine derivatives, their preparation and use
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU1555999A (en) 1997-12-19 1999-07-12 Novo Nordisk A/S 1,2,4-benzothiadiazine derivatives, their preparation and use
HUP0101280A3 (en) 1998-02-18 2003-02-28 Neurosearch As Positive ampa receptor modulator compounds and their use
CA2450236A1 (en) 2001-07-06 2003-01-16 Genentech, Inc. Phage displayed pdz domain ligands
EP1340979A3 (en) 2002-02-27 2004-02-04 Pfizer Limited Neuropeptide receptor and uses thereof
WO2003087089A1 (en) 2002-04-16 2003-10-23 Teijin Limited Piperidine derivatives having ccr3 antagonism
WO2003091245A1 (en) 2002-04-25 2003-11-06 Teijin Limited 4,4-disubstituted piperidine derivatives having ccr3 antagonism
US20050196757A1 (en) 2002-06-21 2005-09-08 Mark Zylka Identification of a receptor controlling migration and metastasis of skin cancer cells
WO2005019191A2 (en) 2003-08-25 2005-03-03 Abbott Laboratories 1, 1-dioxido-4h-1,2,4-benzothiadiazine derivate und verwandte verbindungen als inhibitoren der hcv polymerase zur behandlung von hepatitis c
WO2005028667A1 (ja) 2003-09-19 2005-03-31 Riken ヒト肥満細胞で発現するｇ蛋白質共役型受容体を標的とした薬剤およびそのスクリーニング方法
AU2005205016B2 (en) 2004-01-16 2010-07-15 F. Hoffmann-La Roche Ag 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1H-quinazolin-2-one derivatives and the respective 1H-benzo(1,2,6)thiadiazine-2,2-dioxide and 1,4-dihydro-benzo(D) (1,3)oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-HT) for the treatment of diseases of the central nervous system
EP1794589A4 (en) 2004-09-15 2010-03-17 Protometrix Inc PROTEIN ARRAYS AND METHOD OF USE THEREOF
WO2006062316A1 (en) 2004-12-08 2006-06-15 Electronics And Telecommunications Research Institute Method of controlling base stations to suppress inter-cell interference
US20060217370A1 (en) 2005-02-18 2006-09-28 Ethan Burstein Compounds useful for the treatment and prevention of pain and screening methods therefor
WO2006108584A2 (en) 2005-04-15 2006-10-19 Cenix Bioscience Gmbh Human marker genes and agents for cardiovascular disorders and artherosclerosis
WO2006118328A1 (ja) 2005-04-28 2006-11-09 Takeda Pharmaceutical Company Limited 脱顆粒抑制剤
WO2007032793A1 (en) 2005-05-27 2007-03-22 Sentigen Bioscience, Inc. Multiplex array useful for assaying protein-protein interaction
AU2006308991A1 (en) 2005-10-31 2007-05-10 University Of Rochester Chemical preconditioning as a preventative or treatment for excitotoxic synaptic damage
JP2009060787A (ja) 2005-11-15 2009-03-26 Gunma Univ Ｒｅｃ１６８を介する肥満細胞の脱顆粒反応を抑制する物質のスクリーニング方法及び同定方法、並びにＲｅｃ１６８アンタゴニストを含有してなる肥満細胞が関与する炎症性疾患の治療剤
US20110150897A1 (en) 2006-10-11 2011-06-23 Meyer Thomas F Influenza targets
WO2008052072A2 (en) * 2006-10-24 2008-05-02 Acadia Pharmaceuticals Inc. Compounds for the treatment of pain and screening methods therefor
EP2091556B1 (en) 2006-11-15 2018-07-25 Omeros Corporation Non-human animal comprising a mutation in the sreb2/gpr85 gene as animal model of metabolic disease
UA100120C2 (en) 2007-04-03 2012-11-26 Анадис Фармасьютикалз, Инк. 5,6-dihydro-1h-pyridin-2-one compounds
EP2067861A1 (en) 2007-12-05 2009-06-10 Koninklijke Nederlandse Akademie van Wetenschappen Animals of the rattus genus wherein msh6 expression is functionally decreased and methods for the generation of specific mutants therefrom
JP2012167017A (ja) 2009-06-15 2012-09-06 National Cerebral & Cardiovascular Center ペプチドおよびその用途
CN102597268B (zh) 2009-09-03 2017-09-22 弗·哈夫曼-拉罗切有限公司 用于治疗、诊断和监控类风湿性关节炎的方法
IT1402905B1 (it) 2010-11-29 2013-09-27 Univ Degli Studi Modena E Reggio Emilia Derivati di 1,2,4-benzotiadiazin 1,1-diossido, loro preparazione e loro impiego come modulatori allosterici del recettore ampa.
JP5932279B2 (ja) 2011-10-07 2016-06-08 ポーラ化成工業株式会社 スクリーニング方法
EP2819675A4 (en) 2012-02-27 2015-07-22 Essentialis Inc SALTS OF KALIUM ATP CHANNEL OPENERS AND USES THEREOF
CN104837832B (zh) 2012-10-05 2019-04-26 里格尔药品股份有限公司 Gdf-8抑制剂
EP3011340B1 (en) 2013-06-18 2017-11-22 Bayer Pharma Aktiengesellschaft Mrg receptor modulators
WO2015117024A1 (en) 2014-01-31 2015-08-06 Mayo Foundation For Medical Education And Research Novel therapeutics for the treatment of glaucoma
WO2015157093A1 (en) 2014-04-08 2015-10-15 Rigel Pharmaceuticals, Inc. 2,3-disubstituted pyridine compounds as tgf-beta inhibitors and methods of use
WO2016118632A1 (en) 2015-01-20 2016-07-28 The General Hospital Corporation Prevention and treatment of itch with an mrgpr antagonist
WO2017095759A1 (en) 2015-12-04 2017-06-08 Merck Sharp & Dohme Corp. C5-c6-carbocyclic fused iminothiadiazine dioxides as bace inhibitors, compositions, and their use
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
JP7164542B2 (ja) 2017-04-06 2022-11-01 インベンティバ 新規な化合物であるｙａｐ／ｔａｚ－ｔｅａｄ相互作用阻害剤、および悪性中皮腫の治療でのその使用
CA3064962A1 (en) 2017-05-26 2018-11-29 National Research Council Of Canada Self-assembling peptide for activating human mast cells
HRP20231253T1 (hr) 2018-06-27 2024-02-02 Bristol-Myers Squibb Company Supstituirani spojevi naftiridina korisni kao aktivatori t stanica
EP3597653A1 (en) 2018-07-19 2020-01-22 Irbm S.P.A. Cyclic inhibitors of hepatitis b virus
US12247015B2 (en) 2019-04-29 2025-03-11 Solent Therapeutics, Llc 3-amino-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2

Also Published As

Publication number Publication date
KR20260026093A (ko) 2026-02-25
TWI846868B (zh) 2024-07-01
CN114072393B (zh) 2025-05-27
PE20220425A1 (es) 2022-03-29
DOP2021000223A (es) 2022-01-16
CR20210544A (es) 2022-03-30
MX2021013135A (es) 2021-11-25
WO2020223255A1 (en) 2020-11-05
KR102922478B1 (ko) 2026-02-04
AR119728A1 (es) 2022-01-05
CA3137584A1 (en) 2020-11-05
BR112021021508A2 (pt) 2022-03-22
IL287521B2 (en) 2026-01-01
US12247015B2 (en) 2025-03-11
PH12021552760A1 (en) 2022-08-15
MA55804A (fr) 2022-04-06
SG11202111717XA (en) 2021-11-29
JP7574215B2 (ja) 2024-10-28
CN120535477A (zh) 2025-08-26
TW202106669A (zh) 2021-02-16
AU2020266529B2 (en) 2026-01-29
JOP20210275A1 (ar) 2023-01-30
CN114072393A (zh) 2022-02-18
EP3962901A1 (en) 2022-03-09
IL287521B1 (en) 2025-09-01
CO2021014155A2 (es) 2021-10-29
KR20220012244A (ko) 2022-02-03
AU2020266529A1 (en) 2021-12-16
CL2021002805A1 (es) 2022-07-22
JP2022535672A (ja) 2022-08-10
US20220119361A1 (en) 2022-04-21
IL287521A (en) 2021-12-01
US20250289792A1 (en) 2025-09-18

Similar Documents

Publication Publication Date Title
ECSP21080966A (es) Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2
DOP2022000057A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
CO2022000480A2 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1.8
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
ECSP21034668A (es) Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cáncer
MX381041B (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
PY1923494A (es) Derivados de n-(3-(7h-pirrolo[2,3-d]pirimidin-4-il)fenil)benzamida
PE20050089A1 (es) Derivados de azo [1,2-c] quinazolina condensados
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
UY35376A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
ECSP099394A (es) Derivados de quinuclidinol como antogonistas de receptores muscarínicos
CL2021000844A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
UY29420A1 (es) Derivados de 2-piridona,composiciones que los contienen, procesos de preparación y aplicación
ECSP099046A (es) Derivados ciclopropil amina
MX2020007443A (es) Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de vasculitis y enfermedades inflamatorias.
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
UY28357A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparación de los mismos y sus usos
ECSP22091230A (es) Derivados de n-(piperidin-4-il)benzamida de acción luminal
CL2020000439A1 (es) Sales de un compuesto y sus formas cristalinas.
CL2022002692A1 (es) Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
MX2020013895A (es) Agentes inhibidores de ask1.
CL2024000317A1 (es) Derivados de ciclopentatiofencarboxamida como antagonistas del receptor del factor de activación de plaquetas
CO2021003218A2 (es) Agentes inhibidores de ask1
DOP2017000138A (es) Derivados de fumagilol
UY28711A1 (es) Derivados heterociclicos